Closed System Drug Transfer Device (CSTD) Market to grow 10.17% CAGR during the Forecast Period 2023-2032

Market Research Future (MRFR) has published on the “Global Closed System Drug Transfer Device Market”.

The Global Closed System Drug Transfer Device Market is estimated to register a CAGR of 10.17% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the Global Closed System Drug Transfer Device - B. Braun SE (Germany), JMS Co., Ltd. (Japan), ICU Medical, Inc. (US), Simplivia (Israel), Equashield (US), Becton, Dickinson and Company (US), Baxter International Inc. (US), Cormed (US), Yukon Medical (US), Caragen Ltd. (Ireland).

Market Highlights

The Global Closed System Drug Transfer Device Market is expected to register a CAGR of 10.17% during the forecast period and is estimated to reach USD 2.87 billion by 2032.

The global closed system drug transfer device market is increasing incidences of cancer across the globe and stringent regulatory requirements within the healthcare industry. Additionally, the growing technological advancements in closed-system drug transfer devices (CSTDs) will provide growth opportunities for the market in the future.

Access full report @ https://www.marketresearchfuture.com/reports/closed-system-drug-transfer-device-market-7733

Segment Analysis

The Global Closed System Drug Transfer Device Market has been segmented based on Type, Component, Closing Mechanism, Technology, and End-users.

Based on type, the global closed-system drug transfer device market has been segmented into membrane-to-membrane systems and needless systems. The membrane-to-membrane systems segment dominated the market in 2023, and needless systems is projected to be the fastest-growing segment during the forecast period, 2024–2032. The membrane-to-membrane systems segment has the largest market share of 71.88%.

Based on component, the global closed system drug transfer device market has been segmented into vial access devices, syringe safety devices, bag/line access devices, and accessories. The syringe safety devices segment dominated the market in 2023, and accessories is projected to be the fastest-growing segment during the forecast period, 2024–2032. Closed syringe safety devices facilitate the transfer of fluid using a syringe and various components through dedicated device connections. These devices prevent the wastage of drugs which provides an easy method to deliver hazardous drugs and reduce confusion. Companies such as B. Braun Medical Inc. offer OnGuard syringe adaptor, a closed system drug transfer device for easy delivery of drug to the patient

Based on the closing mechanism, the global closed system drug transfer device market has been segmented into push-to-turn systems, color-to-color alignment systems, leur lock systems, and click-to-lock systems. The leur lock systems segment dominated the market in 2023. Luer lock syringe enables a needle to be twisted onto the tip and locked into place, providing a secure connection, and preventing accidental removal of the needle and injection of contents. Luer lock fittings are securely joined using a tabbed hub on the female fitting which screws into threads in a sleeve on the male fitting. It allows a needle to be twisted onto the tip and then locked in place. An increasing number of manufacturers are producing new and refined drug-delivery products. For instance, Simplivia Healthcare Ltd. (Israel) manufactures Tevadaptor luer lock adaptor which converts any standard female luer lock port (e.g., patient access port) to a safe and closed Tevadaptor connection. The other CSTD closing mechanism includes click to lock systems.

Based on technology, the global closed system drug transfer device market has been segmented into compartmentalized devices, diaphragm-based devices, and air filtration devices. The diaphragm-based devices segment dominated the market in 2023, and air filtration devices are projected to be the fastest-growing segment during the forecast period, 2023–2032. The diaphragm-based devices segment has the largest market share of 42.92%.

Based on end user, the global closed system drug transfer device market has been segmented into hospitals & clinics, specialty centers, and others. The hospitals & clinics segment dominated the market in 2023, and specialty centers is projected to be the fastest-growing segment during the forecast period, 2024–2032. The hospitals and clinics segment accounted for the largest market share of 74.34%. The high adoption of CSTD systems in hospitals & clinics is due to the high purchasing power of big hospitals and the growing healthcare infrastructure

Regional Analysis

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

Based on region, the Global Closed System Drug Transfer Device market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 4.08 billion by 2032, registering a CAGR of 9.10% during the forecast period.

North America accounted for the largest market share of 38.14% and is estimated to dominate the global CSTD market. This large market share is due to the increasing prevalence of cancer cases and the strong research and development infrastructure. For instance, In the United States in 2020, there were 1,603,844 new cancer cases reported and 602,347 cancer deaths. There were 403 new cancer cases reported for every 100,000 people, and 144 people died from cancer. Moreover, Technological advancements in CSTDs are further driving market growth. Modern devices incorporate innovative features such as air filtration systems, leak-proof connectors, and enhanced compatibility with various drug delivery systems, thereby improving their effectiveness and usability in clinical settings

The Americas region is followed by Europe, which accounted for the second largest closed system drug transfer device market share. One of the primary drivers is the increasing prevalence of chronic diseases across the region, which necessitates efficient and safe drug delivery mechanisms. This demographic trend is fueling demand for advanced drug transfer devices that offer enhanced safety and precision in medication administration.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest-growing region over the forecast period due to the increasing number of new vendors involved in the drug-device system, as many regional/small market players are trying to leverage the market share. Additionally, the availability of skilled workforce and low production cost in the region portrays an opportunity for global players to enter untapped markets in Asia-Pacific.

Key Findings of the Study

• 
  

  The Global Closed System Drug Transfer Device Market is expected to reach USD 2.87 billion by 2032, at a CAGR of 10.17% during the forecast period.

  
  


• 
  

  The North America Global Closed System Drug Transfer Device Market accounted for USD 0.41 billion in 2023 and is expected to exhibit a 9.10% CAGR during the study period.

  
  


• 
  

  Braun SE (Germany), JMS Co., Ltd. (Japan), ICU Medical, Inc. (US), Simplivia (Israel), Equashield (US), Becton, Dickinson and Company (US), Baxter International Inc. (US), Cormed (US), Yukon Medical (US), Caragen Ltd. (Ireland) are the key market players.